Are all bisphosphonates the same? potential reasons for clinical differences: A perspective

Journal of Women's Health

Volumn 19, Issue 4, 2010, Pages 719-727

  Simon, James A ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ETIDRONIC ACID; IBANDRONIC ACID; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID;

BINDING AFFINITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; FEMUR SUBTROCHANTERIC FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HIP SURGERY; HUMAN; HYPERCALCEMIA; JAW OSTEONECROSIS; PATHOLOGIC FRACTURE; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STRUCTURE ACTIVITY RELATION; VERTEBRA FRACTURE; WRIST FRACTURE;

BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PROCESS ASSESSMENT (HEALTH CARE);

EID: 77951794991     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2008.1196     Document Type: Review

References (51)

1. National Osteoporosis Foundation. Fast facts on osteoporosis 2008. Available at www.nof.org=osteoporosis= diseasefacts.htm
2. World Health Organization. Osteoporosis: Both health organizations and individuals must act now to avoid an impending epidemic. Press Release WHO=58, October 11, 1999. Available at www.who.int=inf-pr-1999=en=pr99-58.html
3. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-323.
4. Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime osteoporosis impact. Arch Intern Med 1991;151: 2026-2032.
5. Wigderowitz CA, Rowley DI, Mole PA, Paterson CR, Abel EW. Bone mineral density of the radius in patients with Colles' fracture. J Bone Joint Surg Br 2000;82:87-89.
6. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-1541.
7. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 1998;280:2077-2082.
8. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 1999;282:1344-1352.
9. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91.
10. Chesnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-1249.
11. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822.
12. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-1809.
13. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85:4118-4124.
14. Boonen S, Laan RF, Barton IP, Watts NB. Effect of osteoporosis treatments on risk of nonvertebral fractures: Review and meta-analysis of intention-to-treat studies. Osteoporos Int 2005;16:1291-1298.
15. Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: Results of a meta-analysis of phase III studies. Curr Med Res Opin 2008;24:237-245.
16. Cranney A, Wells GA, Yetisir E, et al. Ibandronate for the prevention of nonvertebral fractures: A pooled analysis of individual patient data. Osteoporos Int 2009;20:291-297.
17. Riggs BL, Melton LJ III. The worldwide problem of osteoporosis: Insights afforded by epidemiology. Bone 1995;17: 505S-511S.
18. Pasco JA, Sanders KM, Hoekstra FM, Henry MJ, Nicholson GC, Kotowicz MA. The human cost of fracture. Osteoporos Int 2005;16:2046-2052.
19. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344:333-340.
20. Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70mg compared with once-weekly risedronate 35mg in women with postmenopausal osteoporosis: A randomized double-blind study. J Bone Miner Res 2005;20:141-151.
21. Bonnick S, Saag KG, Kiel DP, et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 2006;91:2631-2637.
22. Miller PD, Epstein S, Sedarati F, Reginster JY. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: Results from the headto-head MOTION study. Curr Med Res Opin 2008;24:207-213.
23. Reid DM, Devogelaer J-P, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocoticoid-induced osteoporosis (HORIZON): A multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009;373:1253-1263.
24. Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004;20:433-439.
25. Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 74:129-135.
26. Felsenberg D, Miller P, Armbrecht G, Wilson K, Schimmer RC, Papapoulos SE. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone 2005;37:651-654.
27. Dowd R, Recker RR, Heaney RP. Study subjects and ordinary patients. Osteoporos Int 2000;11:533-536.
28. Hlatky MA, Lee KL, Harrell FE Jr, et al. Tying clinical research to patient care by use of an observational database. Stat Med 1984;3:375-387.
29. Silverman SL. From randomized controlled trials to observational studies. Am J Med 2009;122:114-120.
30. Lindsay R, Borisov NN, Sheer RL, Steinbuch M. Impact of early osteoporosis treatment on subsequent fracture prevention among women with clinical vertebral fracture. J Bone Miner Res 2005;20(Suppl 1):M293.
31. Watts NB, Worley K, Solis A, Doyle J, Sheer R. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: Results from a managed care administrative claims database. J Manag Care Pharm 2004;10:142-151.
32. Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The Risedronate and Alendronate (REAL) cohort study. Osteoporos Int 2007; 18:25-34.
33. Harris ST, Reginster J-Y, Harley C, et al. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: The eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone 2009;44:758-765.
34. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534.
35. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-1491.
36. Sayeed-Noor AS, Sjödén GO. Case reports: Two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Rel Res 2009;467:1291-1296.
37. Kwek EB, Goh SK, Koh JS, et al. An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy? Injury 2008;39:224-231.
38. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: A caution. J Bone Joint Surg Br 2007;89:349-353.
39. Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004;19:745-751.
40. Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008;93:852-860.
41. Miller PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to teriparatide following therapy with alendronate or risedronate. J Clin Endocrinol Metab 2008;93:3785-3793.
42. Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R. Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos Int 2008;19:529-535.
43. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 2006;38:617-627.
44. Henneman ZJ, Nancollas GH, Ebetino FH, Russell RG, Phipps RJ. Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro. J Biomed Mater Res A 2008;85:993-1000.
45. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogencontaining bisphosphonates. J Pharmacol Exp Ther 2001; 296:235-242.
46. Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA 2006;103:7829-7834.
47. Russell RG. Bisphosphonates: From bench to bedside. Ann NY Acad Sci 2006;1068:367-401.
48. Russell RGG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphophonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-759.
49. Russell RG. Bisphosphonates: Mode of action and pharmacology. Pediatrics 2007;119(Suppl 2):S150-S162.
50. Plotkin LI, Weinstien RS, Parfitt AM, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999;104:1363-1374.
51. Follet H, Li J, Phipps RJ, et al. Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading. Bone 2007;40:1172-1177.